MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

"Increased Prevalence of Chronic Neurological Conditions and Enhanced Healthcare Infrastructure Drive Neurology Market Growth in Unexplored Markets" BOSTON, May 21, 2025 /PRNewswire/ -- ...

According to the latest study from BCC Research, "Neurology Market: A BCC Research Overview" is estimated to increase from ...

This positive market response leaves some investors questioning if Viking Therapeutics' financials and pipeline prospects justify this heightened investor confidence. Viking Therapeutics exceeded ...

Gifting allows recipients to access the article for free. University of Michigan spinout company Courage Therapeutics has raised $7.8 million as part of its seed round, the company announced Friday.

For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas. Rznomics is a clinical-stage ...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its ...

I’m referring to the pending announcement of the first clinical data from Summit Therapeutics and its buzzy PD-1-VEGF antibody ivonescimab derived from lung cancer patients in the U.S. and other ...

For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas. Rznomics is a clinical ...